William Lear, MD
MOHS-Micrographic Surgery · Salem, ORNPI 1558553115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $509, 7.4 times the $69 reported in 2019.
Across 69 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$291
- Lilly USA, LLC$206
- Regeneron Healthcare Solutions, Inc.$190
- Medline Industries LP$153
- Novartis$95
- AbbVie$88
- plus $436 from 13 others
What the payments were for
- Food & beverage$1,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $291 |
| Lilly USA, LLC | 9 | $206 |
| Regeneron Healthcare Solutions, Inc. | 7 | $190 |
| Medline Industries LP | 1 | $153 |
| Novartis | 5 | $95 |
| AbbVie | 4 | $88 |
| Sanofi | 4 | $86 |
| Conmed Corporation | 1 | $57 |
| Incyte Corporation | 2 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| UCB, Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $31 |
| Pfizer | 2 | $31 |
| Smith+Nephew | 1 | $27 |
| LEO Pharma Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Biofrontera Inc. | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Arcutis Biotherapeutics, Inc. | 1 | $13 |
How this compares
Too few mohs-micrographic surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 167 | $12,656 |
| Doxycycline Monohydrate | 13 | $130 |
| Mupirocin | 20 | $125 |
| Cephalexin | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Salem
- Jarett CasaleSalem$6K
- Anna BarPortland$63K
- Wesley YuPortland$15K
- Oliver WiscoBend$13K
- Lindsey FixSpringfield$5K
- Gerald PetersBend$3K
- Jennifer BarklundMedford$2K
- Tamar HajarPortland$2K
- Nolan MaloneyMedford$2K
- Sarah FitzmauricePortland$963
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.